InsidersTradesSigma
Total declarations
Company
▲ Purchases (19 ops.)
▼ Sales (39 ops.)
Insider track record
CEODisclosed buys
19
Disclosed sells
39
T+90 hit rate
0%
T+90 mean return
-27.8%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Treace John T., Chief Executive Officer. Insider active across 1 company, notably Treace Medical Concepts, INC.. Aggregated, 65 disclosures have been logged. Breakdown: 19 buys · 39 sells. Total volume traded: €25.1m. History available since 20 October 2021. The latest transaction was disclosed on 12 May 2026 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Declarations65 total
43,000 shares@ US$2.17390.046% mcap1.5% of flowCommon StockSEC:0001193125-26-224391:0
Canonical exit: 10 Aug 2026 (T+90)
43,000 shares@ US$2.17390.046% mcap1.5% of flowCommon StockSEC:0001193125-26-224391
Canonical exit: 10 Aug 2026 (T+90)
2,063 shares0Common StockSEC:0000950170-25-037574:0
60,000 shares@ US$8.73444.9% of flowCommon StockSEC:0000950170-25-032626:0
Canonical exit: 2 Jun 2025 (T+90)
225,000 shares0Common StockSEC:0000950170-25-008971:0
11,905 shares0Common StockSEC:0000950170-25-005577:0
50,000 shares@ US$5.31262.3% of flowCommon StockSEC:0000950170-24-107401:0
Canonical exit: 15 Dec 2024 (T+90)
84,000 shares@ US$5.96473.1% of flowCommon StockSEC:0000950170-24-098286:0
Canonical exit: 13 Nov 2024 (T+90)
85,000 shares@ US$6.00374.5% of flowCommon StockSEC:0000950170-24-097694:0
Canonical exit: 12 Nov 2024 (T+90)
45,000 shares@ US$5.882.4% of flowCommon StockSEC:0000950170-24-072078:0
Canonical exit: 9 Sept 2024 (T+90)
25,000 shares@ US$6.05310.9% of flowCommon StockSEC:0000950170-24-068023:0
Canonical exit: 29 Aug 2024 (T+90)
25,000 shares@ US$5.20250.8% of flowCommon StockSEC:0000950170-24-066745:0
Canonical exit: 27 Aug 2024 (T+90)
50,000 shares@ US$5.06951.6% of flowCommon StockSEC:0000950170-24-065984:0
Canonical exit: 26 Aug 2024 (T+90)
100,000 shares@ US$5.56175.0% of flowCommon StockSEC:0000950170-24-062435:0
Canonical exit: 15 Aug 2024 (T+90)
150,000 shares@ US$5.11876.9% of flowCommon StockSEC:0000950170-24-059854:0
Canonical exit: 12 Aug 2024 (T+90)
150,000 shares@ US$4.57926.2% of flowCommon StockSEC:0000950170-24-058878:0
Canonical exit: 8 Aug 2024 (T+90)
83,000 shares@ US$4.53042.4% of flowCommon StockSEC:0000950170-24-058986:0
Canonical exit: 8 Aug 2024 (T+90)
46,500 shares@ US$20.126.1% of flowCommon StockSEC:0000950170-24-038822:0
2,064 shares0Common StockSEC:0000950170-24-030472:0
178,325 shares0Common StockSEC:0001209191-24-001590:0
40,000 shares@ US$25.00666.1% of flowCommon StockSEC:0001209191-23-026796:0
50,000 shares@ US$25.86348.0% of flowCommon StockSEC:0001209191-23-021955:0
2,075 shares@ US$24.410.5% of flowCommon StockSEC:0001209191-23-018046:0
37,316 shares@ US$21.545.1% of flowCommon StockSEC:0001209191-23-015075:0
11,929 shares@ US$23.191.7% of flowCommon StockSEC:0001209191-23-006465:0
25 of 65 declarations
About Treace John T.
John T. Treace is the Chief Executive Officer of TREACE MEDICAL CONCEPTS, INC. He leads the company's strategic operations and ensures the implementation of growth objectives. His industry experience enables him to make informed decisions that promote the long-term success of TREACE.
